Kalvista Pharmaceuticals Inc

KALV remains in a Stage 2 advancing regime underpinned by a strong parabolic acceleration, reinforcing a bullish medium-term bias. However, price is severely extended above rising short-term EMAs with RSI and Options Score in extreme overbought territory, signaling near-term exhaustion risk. Execution should be deferred and staged on meaningful pullbacks into the rising EMA zone or the recent breakout support area.

• ↑Ectorly launch generated $1.4M net revenue in Q1, capturing 5% of U.S. HAE prescriptions
• ↑FDA-approved oral on-demand therapy with pediatric NDA filing planned after positive Phase 3 interim data
• ↓Q1 operating expenses totalled $60.4M, including $15M in R&D and SG&A costs